Q&A with Brigham Principal Investigator and Hematologist/Oncologist Ann Mullally

Ann Mullally, MD, is a physician-scientist who sees patients at Dana-Farber Cancer Institute and runs a research laboratory based at BWH. The Mullally lab in the BWH Division of Hematology is investigating the biology and treatment of myeloid malignancies, diseases of blood stem cells that arise in the bone marrow. Mullally’s research focuses on myeloproliferative neoplasms (MPN), which are a group of blood cancers that result in the overproduction of white blood cells, red blood cells and/or platelets. In 2013, researchers identified mutations in an endoplasmic reticulum chaperone protein called calreticulin (CALR) in up to 40 percent of patients with MPN. The Mullally lab recently elucidated the mechanism by which mutations in calreticulin cause MPN. One of the projects the team is currently working on is to understand additional aspects of this pathway to develop new therapeutic strategies to target mutant calreticulin in patients with MPN.

Source: Brigham Clinical & Research News